Results 181 to 190 of about 233,840 (301)

Direct cellular reprogramming and transdifferentiation of fibroblasts on wound healing-Fantasy or reality? [PDF]

Chronic Dis Transl Med, 2023
Du J, Liu X, Wong CWY, Wong KKY, Yuan Z.
europepmc   +1 more source

Waveguide Photoactuators: Materials, Fabrication, and Applications

Advanced Robotics Research, EarlyView.
Waveguide photoactuators convert guided light into mechanical motion. Their tethered‐flexible design enables minimally invasive surgery and confined‐space robotics. This review aims to guide materials selection, device design, and system integration, accelerating the transition of waveguide photoactuators from laboratory prototypes to versatile ...
Minjie Xi, Hemin Pan, Yang Zong, Yongfeng Mei, Jizhai Cui   +4 more
wiley   +1 more source

Cellular reprogramming of H3K27M pediatric high-grade glioma to neuron-like state. [PDF]

Acta Neuropathol Commun
Uthamacumaran A, Horth C, Bareke E, Gravel M, Majewski J.   +4 more
europepmc   +1 more source

Initiation phase cellular reprogramming ameliorates DNA damage in the ERCC1 mouse model of premature aging. [PDF]

Front Aging, 2023
Paine PT, Rechsteiner C, Morandini F, Desdín-Micó G, Mrabti C, Parras A, Haghani A, Brooke R, Horvath S, Seluanov A, Gorbunova V, Ocampo A.   +11 more
europepmc   +1 more source

Spatiotemporal Sequential Delivery of Chidamide Regulates Macrophage Reprogramming in Lymphoma Microenvironment Through HDACs‐STAT3 Pathway

Advanced Science, EarlyView.
Our study identifies the HDACs‐STAT3 axis as key regulator for M2 macrophage accumulation in DLBCL. We developed Chid@M2pep‐EVs/TP, a pH‐responsive drug delivery system for M2 macrophage specific chidamide administration. By coupling M2‐targeted chidamide with EVs‐mediated delivery, this system reprograms M2 to M1 via HDAC inhibition and STAT3 ...
Bo Dai, Shuo Wang, Xiaotong Peng, Kunpeng Wu, Mengyao Wu, Zhaoning Lu, Haoshu Zhong, Xiaohan Qian, Shuiyi Tan, Hui Yang, Tanlezi Sun, Jing Wang, Jie Zhang, Hua Jiang, Yin Tong, Tong Chen   +15 more
wiley   +1 more source

GSH‐Responsive Nanoparticles Enhance Hepatocellular Carcinoma Immunotherapy Through Synergistic Effects of Cuproptosis and PI3K Inhibitor Combination

Advanced Science, EarlyView.
ABSTRACT Cuproptosis, an emerging form of programmed cell death, is capable of inducing mitochondrial dysfunction. Moreover, the PI3K‐AKT‐mTOR signaling pathway contributes to tumor cell progression by reprogramming mitochondrial morphology and function.
Lei Wu, Jintong Na, Xiyu Liu, Dongsheng Tang, Zhungang Yang, Zheng Cao, Xinyue He, Haihua Xiao, Liping Zhong, Yuan Liao, Yongxiang Zhao   +10 more
wiley   +1 more source

Tissue nanotransfection and cellular reprogramming in regenerative medicine and antimicrobial dynamics. [PDF]

Front Bioeng Biotechnol
Shakra MY.
europepmc   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Engineered Mesenchymal Stem Cell–NK Cell Complexes for Spatially Targeted and Functionally Revitalized Cancer Immunotherapy

Advanced Science, EarlyView.
IL‐15‐engineered stem cell–NK cell complexes, assembled via bioorthogonal chemistry, enable effective lung cancer immunotherapy. Abstract Natural killer (NK) cells represent a powerful immunotherapeutic strategy due to their intrinsic cytotoxicity and ability to target tumor cells independently of antigen presentation.
Qian Zhang, Bo Yin, Munaiwaier Sabier, Youlan Yang, Mengling Wu, Zhouping Zhao, Xuanzhi Luo, Yuehong Zhong, Xiuming Zhu, Jie Zhang, Jing Wang, Kai Chen, Fei Ruan, Wei Zhang, Zhimin Lu, Jiong Wang   +15 more
wiley   +1 more source

Editorial: Cellular reprogramming in development, disease, and design of cell-replacement therapies. [PDF]

Front Cell Dev Biol, 2023
Burke ZD, Lyon C, Perán M.
europepmc   +1 more source